• 1
    Coons S, Kaplan R. Assessing health-related quality of life: application to drug therapy. Clin Ther 1992;14:8508.
  • 2
    Fish L, Lewis B. Quality of life issues in the management of ovarian cancer. Semin Oncol 1999;26(Suppl. 1):S329.
  • 3
    Sutherland H, Lockwood G, Boyd N. Ratings of the importance of quality of life variables: therapeutic implications for patients with metastatic breast cancer. J Clin Epidemiol 1990;43:6616.
  • 4
    Chang V, Hwang S, Feuerman M, Kasimis BS. Symptom and quality of life surveys of medical oncology patients at a Veterans Affairs Medical Center: a role for symptom assessment. Cancer 2000;88:117583.
  • 5
    Cella D, Yount S, Du H, et al. Development and Validation of the Functional Assessment of Cancer Therapy—Kidney Symptom Index (FKSI)©. J Supp Oncol 2006;4:1919.
  • 6
    Cella D, Tulsky D, Gray G, et al. The Functional Assessment of Cancer Therapy (FACT) Scale: development and validation of the general measure. J Clin Oncol 1993;11:5709.
  • 7
    Zubrod C, Schneiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chronic Dis 1960;11:733.
  • 8
    Jaeschke R, Singer J, Guyatt G. Measurement of health status: ascertaining the minimal clinically important difference. Controll Clin Trials 1989;10:40715.
  • 9
    McHorney C, Kosinski M, Ware J Jr. Comparisons of the costs and quality of norms for the SF-36 health survey collected by mail versus telephone interview: results from a national survey. Med Care 1994;32:55167.
  • 10
    Lydick E, Epstein R. Interpretation of quality of life changes. Qual Life Res 1993;2:2216.
  • 11
    Guyatt G, Osoba D, Wu A, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002;77:37183.
  • 12
    Cohen J. Statistical Power Analysis for the Behavioral Sciences (2nd ed.). Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
  • 13
    Cella D, Paul D, Yount S, et al. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest 2003;21:52635.